VehikK, CuthbersonD, RuhligH, et al.Long-term outcome of individuals treated with oral insulin. Diabetes Prevention Trial–Type 1 (DPT-1) oral insulin trial. Diabetes Care, 2011; 34: 1585–90.
2.
Cardiff University. Safety study to assess whether proinsulin peptide injections can slow or stop the body damaging its own insulin making cells in the pancreas in patients newly diagnosed with type 1 diabetes (MonoPepT1De) [article online]. Available at https://clinicaltrials.gov/ct2/show/NCT01536431 NLM Identifier: NCT01536431 (accessed July2015).
3.
VoltarelliJC, CouriCEB, StracieriABPL, et al.Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA, 2007; 297: 1568–76.
4.
HallerMJH, CintronM, McGrailK, BruskoTM, WasserfallC, HulmeM, MathewsCE, AtkinsonMA, SchatzDA. Granulocyte colony stimulating factor (GCSF) fails to preserve beta-cell function in patients with recent onset type 1 diabetes (T1D). Diabetes, 2014; 63: A428.
5.
GitelmanSE, GottliebPA, RigbyMR, et al.Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol, 2013; 1: 306–16.
6.
National Institute of Diabetes and Digestive and Kidney Diseases. ATG-GCSF in new onset type 1 diabetes [article online]. Available at https://clinicaltrials.gov/ct2/show/NCT02215200 NLM Identifier: NCT02215200 (accessed July2015).
7.
KeymeulenB, VandemeulebrouckeE, ZieglerAG. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med, 2005; 352: 2598–608.
8.
HeroldKC, GitelmanS, GreenbaumC, et al.Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol, 2009; 132: 166–73.
9.
National Institute of Diabetes and Digestive and Kidney Diseases. Teplizumab for prevention of type 1 diabetes in relatives “at-risk” [article online]. Available from https://clinicaltrials.gov/ct2/show/NCT01030861 NLM Identifier: NCT01030861 (accessed July2015).
10.
LongSA, RieckM, SandaS, et al.Diabetes TrialNet and the Immune Tolerance Network. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes, 2012; 61: 2340–48.
11.
OrbanT, BundyB, BeckerDJ, et al.Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care, 2014; 37: 1069–75.
